Adjuvant sorafenib and sunitinib do not improve outcomes in locally advanced kidney cancer Date: February 24, 2015 Source: American Society of Clinical Oncology (ASCO) Summary: Findings from a ...

Purpose: The role of sunitinib and sorafenib in the treatment of metastatic renal cell carcinoma (mRCC) is reviewed. Conclusion: The tyrosine kinase inhibitors sorafenib and sunitinib offer ...

On the basis of the promising preliminary activity in renal cell carcinoma (RCC) patients across the Phase I trials, Bayer and Onyx decided to evaluate sorafenib monotherapy as a treatment for RCC ...

Sorafenib patients who progressed were dose-escalated ... assessed by Functional Assessment of Cancer Therapy (FACT)-Kidney Symptom Index-15 (FKSI-15), FACT-Biologic Response Modifier (FACT-BRM), and ...

Sorafenib is US FDA approved for the treatment of advanced renal cell carcinoma and unresectable hepatocellular carcinoma. The recommended single-agent dose is 400 mg orally twice a day ...

Nexavar is also already licensed to treat renal cell carcinoma (kidney cancer) and added its third indication, for differentiated thyroid carcinoma (DTC), in November last year. The drug has been ...

The approval was based on data from a phase 3 TIVO-3 study that compared tivozanib to sorafenib in adults ... relapsed or refractory advanced renal cell carcinoma (RCC) after 2 or more prior ...

What Is Renal Cell Carcinoma? It's the most common type of kidney cancer. Although it’s a serious disease, finding and treating it early makes it more likely that you’ll be cured. No matter ...